High incidence of secondary malignancies after allogeneic haematopoietic stem cell transplantation

被引：0
|
作者：
Neuburger, S. [1 ]
Hemmati, P. [1 ]
Massenkeil, G. [2 ]
Terwey, T. [1 ]
Kim, T. [1 ]
le Coutre, P. [1 ]
Doerken, B. [1 ]
Arnold, R. [1 ]
机构：
[1] Charite Virchow Klinikum, Berlin, Germany
[2] Klinikum Stadt Ludwigshafen, Gutersloh, Germany
来源：
BONE MARROW TRANSPLANTATION | 2009年 / 43卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S170 / S170
页数：1
相关论文
共 50 条
  • [31] Disseminated adenovirus infections after allogeneic haematopoietic stem cell transplantation: incidence, risk factors and outcome
    Robin, M.
    Marquet-Juillet, S.
    Scieux, C.
    de latour, R. Peffault
    Esperou, H.
    Ferry, C.
    Rocha, V.
    Molina, J.
    Bergeron, A.
    Devergie, A.
    Gluckman, E.
    Ribaud, P.
    Socie, G.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S30 - S30
  • [32] AZACITIDINE FOR RELAPSE TREATMENT IN MYELOID MALIGNANCIES FOLLOWING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION
    Tessoulin, B.
    Chevallier, P.
    LeGouill, S.
    Moreau, P.
    Peterlin, P.
    LeBourgeois, A.
    Mohty, M.
    Guillaume, T.
    HAEMATOLOGICA, 2013, 98 : 28 - 28
  • [33] Second malignancies after autologous haematopoietic stem cell transplantation in children
    Jacobsohn, D.
    Danner-Koptik, K.
    Brazauskas, R.
    Wang, Z.
    Duncan, C.
    Sorror, M.
    Majhail, N.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S20 - S20
  • [34] Azacitidine for relapse treatment in myeloid malignancies following allogeneic haematopoietic stem cell transplantation
    Tessoulin, T.
    Mohty, M.
    Delaunay, J.
    Legouill, S.
    Moreau, P.
    Chevallier, P.
    Precupanu, C.
    Gastinne, T.
    Loirat, M.
    Guillaume, T.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S256 - S257
  • [35] Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies
    Adhikari, Janak
    Sharma, Priyadarshani
    Bhatt, Vijaya Raj
    FUTURE ONCOLOGY, 2015, 11 (23) : 3175 - 3185
  • [36] Secondary malignancy after allogeneic stem cell transplantation: Incidence and risk factors.
    Hosing, C
    Saliba, RM
    De Lima, M
    Giralt, S
    Ghosh, S
    Hsu, Y
    Anderlini, P
    Hymes, SR
    Andersson, B
    Khouri, IF
    Champlin, R
    Couriel, D
    BLOOD, 2005, 106 (11) : 327A - 327A
  • [37] Secondary malignancies after hematopoietic stem cell transplantation
    Roziakova, L.
    Bojtarova, E.
    Mistrik, M.
    Mladosievicova, B.
    NEOPLASMA, 2011, 58 (01) : 1 - 8
  • [38] Secondary malignancies after hematopoietic stem cell transplantation
    Ghelani, D
    Saliba, R
    de Lima, M
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 56 (01) : 115 - 126
  • [39] Reconstitution of NK cell phenotype after allogeneic haematopoietic stem cell transplantation
    Giebel, S.
    Dziaczkowska, J.
    Czerw, T.
    Kruzel, T.
    Wojnar, J.
    Krawczyk-Kulis, M.
    Markiewicz, M.
    Wylezol, I.
    Holowiecka-Goral, A.
    Kusnierczyk, P.
    Holowiecki, J.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S223 - S223
  • [40] CMV resistance in patients after allogeneic haematopoietic stem cell transplantation
    Hubacek, P.
    Kouba, M.
    Boutolleau, D.
    Pliskova, L.
    Vejrazkova, E.
    Keslova, P.
    Sedlacek, P.
    Cetkovsky, P.
    JOURNAL OF CLINICAL VIROLOGY, 2015, 70 : S125 - S126
12345